Valerie Humblet
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$14.1MFederal grants as PI21 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
21 awards · $14.1M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 21, 2025 | NIH | SBIR Phase II Theranostic for gastric cancer | $1.1M | COLLAGEN MEDICAL LLC |
| Aug 30, 2024 | NIH | SBIR Phase II Theranostic for gastric cancer | $885K | COLLAGEN MEDICAL LLC |
| Sep 11, 2023 | NIH | SBIR Phase II Theranostic for gastric cancer | $396K | COLLAGEN MEDICAL LLC |
| May 31, 2023 | NIH | SBIR Phase II PET imaging of radiation induced lung injury | $805K | COLLAGEN MEDICAL LLC |
| Aug 8, 2022 | NIH | SBIR Phase II PET imaging of radiation induced lung injury | $1.2M | COLLAGEN MEDICAL LLC |
| Jun 1, 2022 | NIH | SBIR Phase II PET imaging of radiation induced lung injury | $2.0M | COLLAGEN MEDICAL LLC |
| May 13, 2022 | NIH | SBIR Phase II Targeted Imaging of Fibrosis in the Left Atrium | $726K | COLLAGEN MEDICAL LLC |
| Sep 1, 2021 | NIH | SBIR Phase I New class of collagen-targeted contrast agents for Magnetic Resonance Imaging | $287K | COLLAGEN MEDICAL LLC |
| Aug 20, 2021 | NIH | SBIR Phase I New class of collagen-targeted contrast agents for Magnetic Resonance Imaging | $287K | COLLAGEN MEDICAL LLC |
| Apr 30, 2021 | NIH | SBIR Phase II Targeted Imaging of Fibrosis in the Left Atrium | $766K | COLLAGEN MEDICAL LLC |
| Feb 25, 2021 | NIH | SBIR Phase II Molecular Imaging Agent to Detect Thrombus | $497K | COLLAGEN MEDICAL LLC |
| May 4, 2020 | NIH | SBIR Phase II PET imaging of radiation induced lung injury | $400K | COLLAGEN MEDICAL LLC |
| Sep 16, 2019 | NIH | SBIR Phase I Magnetic Particle Detection Test for Vulnerable Carotid Plaque | $300K | COLLAGEN MEDICAL LLC |
| Sep 6, 2018 | NIH | SBIR Phase II Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer | $210K | COLLAGEN MEDICAL LLC |
| Aug 13, 2018 | NIH | SBIR Phase II Targeted Imaging of Fibrosis in the Left Atrium | $295K | COLLAGEN MEDICAL LLC |
| Aug 7, 2017 | NIH | SBIR Phase II Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer | $1.0M | COLLAGEN MEDICAL LLC |
| Sep 9, 2016 | NIH | SBIR Phase II Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer | $998K | COLLAGEN MEDICAL LLC |
| Apr 14, 2016 | NIH | SBIR Phase II CM-65, a Targeted Contrast Agent for Cardiac Magnetic Resonance Perfusion Imaging | $430K | COLLAGEN MEDICAL LLC |
| Sep 24, 2015 | NIH | SBIR Phase II Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer | $300K | COLLAGEN MEDICAL LLC |
| May 15, 2015 | NIH | SBIR Phase II CM-65, a Targeted Contrast Agent for Cardiac Magnetic Resonance Perfusion Imaging | $858K | COLLAGEN MEDICAL LLC |
| May 12, 2015 | NIH | SBIR Phase II CM-65, a Targeted Contrast Agent for Cardiac Magnetic Resonance Perfusion Imaging | $427K | COLLAGEN MEDICAL LLC |
Peer ranks
Federal funding#27
Awards as PI#21
Patents#505
Companies
- COLLAGEN MEDICAL LLCLinked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.